Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors
Interventions: DRUG: LAG525|DRUG: PDR001
Sponsor: Novartis Pharmaceuticals